Holen Sie sich die Stockscreener-App
18.28
9.05%
-1.82
Handel nachbörslich:
18.15
-0.13
-0.71%
Schlusskurs vom Vortag:
$20.10
Offen:
$22
24-Stunden-Volumen:
230.18K
Relative Volume:
2.43
Marktkapitalisierung:
$136.46M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-156.09M
KGV:
-0.7617
EPS:
-24
Netto-Cashflow:
$-102.69M
1W Leistung:
-9.59%
1M Leistung:
-11.22%
6M Leistung:
+31.23%
1J Leistung:
+52.59%
1-Tages-Spanne:
$17.68
$22.63
1-Wochen-Bereich:
$17.68
$22.63
52-Wochen-Spanne:
$9.62
$92.00
Instil Bio Inc Stock (TIL) Company Profile
Firmenname
Instil Bio Inc
Sektor
Branche
Telefon
(972) 499-3350
Adresse
3963 MAPLE AVENUE, DALLAS
Vergleichen Sie TIL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TIL
Instil Bio Inc
|
18.28 | 136.46M | 0 | -156.09M | -102.69M | -24.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Instil Bio Inc Stock (TIL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-04 | Eingeleitet | JMP Securities | Mkt Perform |
| 2024-04-12 | Herabstufung | Jefferies | Buy → Hold |
| 2022-11-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-11-01 | Herabstufung | Truist | Buy → Hold |
| 2021-08-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-04-13 | Eingeleitet | Cowen | Outperform |
| 2021-04-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-04-13 | Eingeleitet | Truist | Buy |
Alle ansehen
Instil Bio Inc Aktie (TIL) Neueste Nachrichten
Institutions along with private equity firms who hold considerable shares inInstil Bio, Inc. (NASDAQ:TIL) come under pressure; lose 12% of holdings value - Simply Wall St
Instil Bio: Time To Hop On The Summit Wave? (NASDAQ:TIL) - Seeking Alpha
(TIL) Technical Data - Stock Traders Daily
Private equity firms who hold 38% of Instil Bio, Inc. (NASDAQ:TIL) gained 34%, institutions profited as well - Yahoo Finance
(TIL) Investment Report - Stock Traders Daily
What Makes Instil Bio (TIL) a New Buy Stock - MSN
Instil Bio Announces Clinical Progress in China for - GlobeNewswire
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody - Marketscreener.com
Instil Bio Advances Lung Cancer Treatment: First Patient Dosed in Phase 1b/2 Trial of Novel PD-L1xVEGF Therapy - StockTitan
Instil Bio Stock Soars After Jefferies Upgrade On 'Early Mover' Cancer Drug Candidate: Retail Jubilant - MSN
Jefferies Upgrades Instil Bio (TIL) - MSN
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside - Benzinga
How To Trade (TIL) - Stock Traders Daily
Instil Bio Secures Loan to Refinance Facility - MSN
Long Term Trading Analysis for (TIL) - Stock Traders Daily
Trend Tracker for (TIL) - Stock Traders Daily
Instil Bio’s Strategic Shift To SYN-2510: A Speculative ‘Buy’ Opportunity (NASDAQ:TIL) - Seeking Alpha
(TIL) Trading Report - Stock Traders Daily
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy - Yahoo Finance
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Instil Bio Secures Global Rights to PD-L1xVEGF Drug, Reports $122.9M Cash Position | TIL Stock News - StockTitan
2 Stocks Up Over 700% in 2024 That Could Soar Even Further - AOL
JMP Securities initiates Instil Bio shares at Market Perform on public offering - Investing.com Australia
Instil Bio, Inc.'s (NASDAQ:TIL) stock price dropped 18% last week; private equity firms would not be happy - Simply Wall St
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising? - The Motley Fool
Summit Stock Skyrockets Nearly 700% YTD: Time to Sell or Hold? - Nasdaq
Analysis of Curative Ventures V LLC's Strategic Reduction in Instil Bio Inc - GuruFocus.com
(TIL) Long Term Investment Analysis - Stock Traders Daily
Baird maintains price target on Instil Bio stock, stays upbeat - Investing.com
5 Top NASDAQ Biotech Stocks of 2024 - Nasdaq
FDA Oncology Approvals Accelerate as Global Cancer Rates Set to Climb 77% - Baystreet.ca
Instil Bio Stock Skyrockets 641% in One Week: Here's Why - MSN
BOXER CAPITAL, LLC Acquires New Stake in Instil Bio Inc - GuruFocus.com
Perceptive Advisors LLC Acquires New Stake in Instil Bio Inc - GuruFocus.com
Baird sees Instil Bio stock upside on promising SYN-2510 clinical data - Investing.com
Fantastic Fest 2024: Clowns Rule at Texas’ No-Joke Genre Event Set to Debut ‘Terrifier 3,’ ‘V/H/S Beyond,’ and More - IndieWire
B. Riley Analysts Decrease Earnings Estimates for Inspired Entertainment, Inc. (NASDAQ:INSE) - Defense World
The time has not yet come to remove your chips from the table: Instil Bio Inc (TIL) - SETE News
Financial Metrics Unveiled: Instil Bio Inc (TIL)’s Key Ratios in the Spotlight - The Dwinnex
Instil Bio (TIL) Stock Rises In Extended Session On Major Strategy Reveal - Stocks Telegraph
Inspired Entertainment, Inc. to Post Q3 2024 Earnings of $0.22 Per Share, B. Riley Forecasts (NASDAQ:INSE) - Defense World
Ice Nine Kills to Release Official Song for Slasher Film Terrifier 3 - MetalSucks
Baird retains price target, outperform rating on Instil Bio shares By Investing.com - Investing.com Australia
Ice Nine Kills are releasing a new single for Terrifier 3 - Kerrang!
Ice Nine Kills’ Upcoming Single “A Work of Art” to Feature on "Terrifier 3" Soundtrack - Ghost Cult Magazine
Here's Why Everyone's Talking About Summit Therapeutics - MSN
Finanzdaten der Instil Bio Inc-Aktie (TIL)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.45%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):